CSIMarket
 


Allakos Inc   (ALLK)
Other Ticker:  
 
 

ALLK's Capital Expenditures Growth by Quarter and Year

Allakos Inc 's Capital Expenditures results by quarter and year




ALLK Capital Expenditures (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - 15.42 0.01 0.08
III Quarter September 2.34 10.50 0.02 0.50
II Quarter June 3.11 6.39 0.05 0.12
I Quarter March 2.59 0.92 0.07 2.69
FY   8.04 33.23 0.15 3.39



ALLK Capital Expenditures third quarter 2022 Y/Y Growth Comment
Allakos Inc reported drop in Capital Expenditures in the third quarter 2022 by -77.69% to $ 2.34 millions, from the same quarter in 2021.
The fall in the third quarter 2022 Allakos Inc 's Capital Expenditures compares unfavorably to the Company's average Capital Expenditures jump of 89.5%.

Looking into third quarter 2022 results within Major Pharmaceutical Preparations industry 172 other companies have achieved higher Capital Expenditures growth. While Allakos Inc ' s Capital Expenditures meltdown of -77.69% ranks overall at the positon no. 2296 in the third quarter 2022.




ALLK Capital Expenditures ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - 154100 % -87.5 % -96.93 %
III Quarter September -77.69 % 52400 % -96 % -
II Quarter June -51.33 % 12680 % -58.33 % -
I Quarter March 181.52 % 1214.29 % -97.4 % -
FY   - 22053.33 % -95.58 % -

Financial Statements
Allakos Inc 's third quarter 2022 Capital Expenditures $ 2.34 millions ALLK's Income Statement
Allakos Inc 's third quarter 2021 Capital Expenditures $ 10.50 millions Quarterly ALLK's Income Statement
New: More ALLK's historic Capital Expenditures Growth >>


ALLK Capital Expenditures (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - 46.86 % -50 % -84 %
III Quarter September -24.66 % 64.32 % -60 % 316.67 %
II Quarter June 20.08 % 594.57 % -28.57 % -95.54 %
I Quarter March -83.2 % 9100 % -12.5 % 3.07 %
FY (Year on Year)   - 22053.33 % -95.58 % -




Capital Expenditures third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #173
Healthcare Sector #469
Overall #2296

Capital Expenditures Y/Y Growth Statistics
High Average Low
639.66 % 89.5 % -77.23 %
(Jun 30 2021)   (Dec 31 2019)
Capital Expenditures third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #173
Healthcare Sector #469
Overall #2296
Capital Expenditures Y/Y Growth Statistics
High Average Low
639.66 % 89.5 % -77.23 %
(Jun 30 2021)   (Dec 31 2019)

Capital Expenditures by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Allakos Inc 's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
598.03 % 42.01 % -95.49 %
(Jun 30 2021)  


ALLK's III. Quarter Q/Q Capital Expenditures Comment
In the III. Quarter 2022 Allakos Inc reported fall in Capital Expenditures sequentially by -24.66% to $ 2.34 millions, from $ 3.11 millions released in the previous quarter.

Even seasonal influence that commonly energize III. Quarter 2022 results, were not able to recover the III. Quarter for the Allakos Inc , Alexander Thomas, Major Pharmaceutical Preparations industry contributor allocated in New York said, he cited some pessimism for the ALLK's perspective.

Within Major Pharmaceutical Preparations industry 133 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Allakos Inc 's Capital Expenditures growth quarter on quarter, overall rank is 1871.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #134
Healthcare Sector #356
Overall #1871
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #134
Healthcare Sector #356
Overall #1871
Capital Expenditures Q/Q Growth Statistics
High Average Low
598.03 % 42.01 % -95.49 %
(Jun 30 2021)  


ALLK's III. Quarter Q/Q Capital Expenditures Comment
In the III. Quarter 2022 Allakos Inc realized fall in Capital Expenditures from the second quarter by -24.66% to $ 2.34 millions, from $ 3.11 millions achived in the previous reporting period.

Even periodic influence that commonly fuel III. Quarter 2022 results, could not salvage the III. Quarter for the Allakos Inc , Alexander Thomas, Major Pharmaceutical Preparations industry contributor allocated in New York said.

Within Major Pharmaceutical Preparations industry 133 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Allakos Inc 's Capital Expenditures growth quarter on quarter, overall rank is 1871.


Allakos Inc 's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Sep 30 2022)
12 Months Ending
(Jun 30 2022)
12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
Cumulative Capital Expenditures 12 Months Ending $ 23.46 $ 31.62 $ 34.90 $ 33.22 $ 17.81
Y / Y Capital Expenditures Growth (TTM) 31.77 % 331.35 % 3421.19 % 22047.33 % 7920.72 %
Year on Year Capital Expenditures Growth Overall Ranking # 970 # 85 # 17 # 5 # 5
Seqeuential Capital Expenditures Change (TTM) -25.79 % -9.39 % 5.04 % 86.57 % 142.92 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 2296 # 1541 # 1358 # 105 # 58




Cumulative Capital Expenditures growth Comment
With the quarterly Capital Expenditures reported in the Sep 30 2022 period, Allakos Inc 's cumulative twelve months Capital Expenditures were $ 23 millions, company would post below average annual Capital Expenditures growth of 142.92% year on year, if the fiscal year would end at Sep 30 2022.
A slow-down in the Allakos Inc 's Capital Expenditures growth from the 3.11% growth in Jun 30 2022.

In the Healthcare sector 179 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 85 to 970.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
639.66 %
89.5 %
-77.23 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 173
Healthcare Sector # 180
Overall # 970

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
22047.33 %
3130.12 %
-96.25 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 173
Sector # 469
S&P 500 # 2296
Cumulative Capital Expenditures growth Comment
With the quarterly Capital Expenditures reported in the Sep 30 2022 period, Allakos Inc 's cumulative twelve months Capital Expenditures were $ 23 millions, company would post below average annual Capital Expenditures growth of -96.25% year on year, if the fiscal year would end at Sep 30 2022.
A slow-down in the Allakos Inc 's Capital Expenditures growth from the 3.11% growth in Jun 30 2022.

In the Healthcare sector 179 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 85 to 970.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
639.66 %
89.5 %
-77.23 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 173
Healthcare Sector # 180
Overall # 970

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
22047.33 %
3130.12 %
-96.25 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 173
Sector # 469
S&P 500 # 2296




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
ALLK's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for ALLK's Competitors
Capital Expenditures Growth for Allakos Inc 's Suppliers
Capital Expenditures Growth for ALLK's Customers

You may also want to know
ALLK's Annual Growth Rates ALLK's Profitability Ratios ALLK's Asset Turnover Ratio ALLK's Dividend Growth
ALLK's Roe ALLK's Valuation Ratios ALLK's Financial Strength Ratios ALLK's Dividend Payout Ratio
ALLK's Roa ALLK's Inventory Turnover Ratio ALLK's Growth Rates ALLK's Dividend Comparisons



Companies with similar Capital Expenditures fall for the quarter ending Sep 30 2022 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Sep 30 2022
Tela Bio Inc -0.34%$ -0.344 millions
Edwards Lifesciences Corporation-1.32%$ -1.318 millions
Guardant Health Inc -1.91%$ -1.910 millions
Seagen Inc -2.56%$ -2.556 millions
Addus Homecare Corporation-3.00%$ -2.999 millions
Concert Pharmaceuticals Inc -3.03%$ -3.030 millions
Merck and Co Inc -3.92%$ -3.925 millions
Precision Optics Corporation Inc -3.93%$ -3.925 millions
Nextcure Inc -4.32%$ -4.317 millions
Cvs Health Corporation-4.61%$ -4.605 millions
Electromed inc -5.19%$ -5.185 millions
Sight Sciences Inc -5.23%$ -5.226 millions
Veracyte Inc -5.41%$ -5.408 millions
Baxter International Inc -6.15%$ -6.145 millions
Natera Inc -7.06%$ -7.057 millions
Sio Gene Therapies Inc -7.14%$ -7.143 millions
Replimune Group Inc -7.48%$ -7.477 millions
Rockwell Medical inc -7.87%$ -7.874 millions
Harvard Bioscience Inc-7.92%$ -7.917 millions
Bristol myers Squibb Company-8.52%$ -8.519 millions
Davita Inc -8.54%$ -8.535 millions
Dentsply Sirona Inc -8.57%$ -8.571 millions
Sunlink Health Systems Inc -9.83%$ -9.827 millions
Moderna Inc -10.10%$ -10.101 millions
Te Connectivity Ltd -10.17%$ -10.169 millions
Rhythm Pharmaceuticals inc -10.38%$ -10.377 millions
Sarepta Therapeutics Inc -10.93%$ -10.930 millions
West Pharmaceutical Services Inc -11.49%$ -11.485 millions
Recursion Pharmaceuticals Inc -11.78%$ -11.776 millions
Cytek Biosciences Inc -12.08%$ -12.080 millions


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

DFCO's Profile

Stock Price

DFCO's Financials

Business Description

Fundamentals

Charts & Quotes

DFCO's News

Suppliers

DFCO's Competitors

Customers & Markets

Economic Indicators

DFCO's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071